A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Pfizer
University of Texas Southwestern Medical Center
Case Comprehensive Cancer Center
OHSU Knight Cancer Institute
UNICANCER
Central Hospital Saint Quentin
Academic and Community Cancer Research United
Taipei Medical University Hospital
Sunnybrook Health Sciences Centre
University College, London
AHS Cancer Control Alberta
National Institute of Oncology, Hungary